A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease

BACKGROUND: Multicentric Castleman disease (MCD) is a rare, systemic lymphoproliferative disorder driven by interleukin (IL)-6 overproduction. Siltuximab, an anti-IL-6 monoclonal antibody, has demonstrated durable tumor and symptomatic responses in a multinational, randomized, placebo-controlled stu...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: van Rhee, Frits, Casper, Corey, Voorhees, Peter M., Fayad, Luis E., van de Velde, Helgi, Vermeulen, Jessica, Qin, Xiang, Qi, Ming, Tromp, Brenda, Kurzrock, Razelle
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2015
Sujets:
Clinical Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4745809/
https://ncbi.nlm.nih.gov/pubmed/26327301
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires